Shares of Flamel Technologies SA (NASDAQ:FLML) were down 3.5% on Wednesday . The company traded as low as $13.36 and last traded at $13.37, with a volume of 120,932 shares trading hands. The stock had previously closed at $13.86.

A number of analysts have weighed in on FLML shares. Leerink Swann reiterated a “buy” rating and issued a $16.00 price target on shares of Flamel Technologies SA in a research report on Tuesday, May 10th. Zacks Investment Research upgraded Flamel Technologies SA from a “sell” rating to a “hold” rating in a research report on Tuesday, July 12th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Flamel Technologies SA presently has a consensus rating of “Buy” and a consensus target price of $18.63.

The company has a 50-day moving average price of $13.10 and a 200-day moving average price of $11.10. The firm has a market cap of $551.39 million and a P/E ratio of 32.37.

Flamel Technologies SA (NASDAQ:FLML) last released its quarterly earnings data on Monday, August 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.06 by $0.08. During the same period last year, the firm posted $0.34 earnings per share. The firm earned $38.90 million during the quarter, compared to the consensus estimate of $32.80 million. The firm’s revenue was down 20.0% on a year-over-year basis. On average, equities research analysts expect that Flamel Technologies SA will post ($1.11) EPS for the current year.

In other news, Director Craig R. Stapleton purchased 20,000 shares of the company’s stock in a transaction that occurred on Friday, August 26th. The stock was acquired at an average cost of $13.76 per share, with a total value of $275,200.00. Following the acquisition, the director now owns 509,678 shares in the company, valued at approximately $7,013,169.28. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Michael S. Anderson purchased 5,000 shares of the company’s stock in a transaction that occurred on Monday, August 22nd. The shares were purchased at an average cost of $14.30 per share, with a total value of $71,500.00. The disclosure for this purchase can be found here.

Flamel Technologies SA is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its polymer based technology. The Company has a balanced business model consisting of an Unapproved Marketed Drugs (UMDs) business with over two approved products in the United States, Bloxiverz (neostigmine methylsulfate injection) and Vazculep (phenylephrine hydrochloride injection) that are marketed; a branded pediatric business, and a branded business, focusing on the development of products utilizing Flamel’s drug delivery platforms.